Introduction/Overview
Natural products, as an important treasure trove for drug discovery, play an irreplaceable role in the history of human disease treatment. Among them, diterpenes have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and significant biological activity. Rhodojaponen III (CAS number: 26342-66-5), as a species derived from the Rhododendron family plant Rhododendron（Rhododendron molle）The diterpenoid compounds isolated from Chinese medicine have attracted widespread attention from researchers in recent years due to their broad pharmacological activities, especially their potential anti-tumor effects. Traditionally, Rhododendron amurense is used in folk medicine to treat rheumatism, rheumatism, pain, and injuries caused by falls, but its toxicity is also known. Modern research aims to isolate its active ingredients, elucidate its mechanism of action, in order to reduce toxicity while retaining its efficacy, and develop new therapeutic drugs. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, pharmacological evaluation, and clinical application prospects of Naoyanghuasu III, providing comprehensive scientific references for further research and development.
Chemical structure and physicochemical properties
Naoyanghuasu III belongs to the grayanane type diterpenoid compound, with a molecular formula of C20H32O6 and a molecular weight of 368.4700. Its core structure consists of five fused rings (A/B/C/D/E), where ring A is a six membered ring, ring B is a five membered ring, ring C is a seven membered ring, ring D is a five membered ring, and ring E is an oxygen-containing five membered lactone ring, which is a typical feature of grayanane type diterpenes. The structure contains multiple hydroxyl and carbonyl groups, giving it a certain polarity and reactivity.
Based on its chemical structure calculation, the drug properties related parameters show that its lipid water partition coefficient (LogP) is 0.8755, indicating that it has moderate lipophilicity. The topological polar surface area (TPSA) is 113.68 Å ², reflecting the presence of polar functional groups (such as hydroxyl and carbonyl) in the molecule, which can affect its solubility and membrane permeability. Its water solubility value is 0.7175 mg/mL, belonging to the range of slightly soluble to soluble. These physical and chemical properties suggest that Naoyanghuasu III has certain pharmacological properties, but its high polar surface area may limit its passive diffusion ability on the cell membrane. In addition, the prediction shows that its blood-brain barrier permeability is low, suggesting that it may not easily enter the central nervous system; The negative risk of hERG inhibition indicates a low potential risk of arrhythmia; The Ames test predicted a result of 0.0, indicating that there may be no direct genetic toxicity risk. These preliminary computer predictions provide important directions for subsequent experimental research.
Plant sources and extraction methods
Naoyanghuasu III is mainly derived from the Ericaceae plant Rhododendron genus Rhododendron（Rhododendron molle The leaves, flowers, and roots of Blume G. Don. Rhododendron is widely distributed in the Yangtze River Basin and southern regions of China, and is a toxic ornamental and medicinal plant. The whole plant contains multiple grayanane type diterpenoid toxins, among which kaempferol III is one of the important active ingredients.
The extraction and separation of kaempferol III from plant materials typically involves the use of organic solvent extraction combined with modern chromatographic techniques. The conventional process is as follows: first, dry and crushed Rhododendron leaves are extracted or refluxed with polar solvents such as methanol or ethanol, and then concentrated to obtain the crude extract. The crude extract was subsequently subjected to gradient extraction using solvents such as petroleum ether, ethyl acetate, and n-butanol, and kaempferol III was mainly enriched in the ethyl acetate fraction. Further purification depends on column chromatography technology. Silica gel, reversed phase silica gel (such as ODS) or Sephadex gel (LH-20) are often used as the stationary phase, and chloroform methanol, petroleum ether ethyl acetate or methanol water solvent systems with different proportions are used for elution. High performance liquid chromatography (HPLC), especially preparative HPLC, is the final key step in obtaining high-purity kaempferol III monomer. In recent years, green technologies such as supercritical fluid extraction have also been explored to improve extraction efficiency and selectivity. During the extraction process, attention should be paid to operational safety, as both the raw materials and extracts of Rhododendron amurense have certain toxicity.
Pharmacological activity research
A large number of in vitro and in vivo pharmacological studies have shown that kaempferol III has various biological activities, among which the most prominent is its anti-tumor effect.
1. Antitumor activity:
Naoyanghuasu III exhibits significant proliferation inhibition and pro apoptotic activity on various human tumor cell lines. Studies have confirmed that it has strong cytotoxicity to breast cancer (such as MCF-7, MDA-MB-231), liver cancer (HepG2, SMMC-7721), lung cancer (A549), colon cancer (HCT-116, SW480), ovarian cancer (SKOV3), leukemia (HL-60) and other cells, and its IC50 values are mostly in the micromolar or even nanomolar level. In vivo experiments also support its anti-tumor effect. In a nude mouse transplant tumor model, kaempferol III can dose dependently inhibit tumor growth and show lower signs of systemic toxicity compared to certain chemotherapy drugs.
2. Anti inflammatory activity:
In addition to anti-tumor effects, the traditional application basis of crocetin III - anti-inflammatory activity - has also been validated by modern research. In the lipopolysaccharide (LPS) - induced macrophage (such as RAW264.7) inflammation model, kaempferol III can effectively inhibit the production of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines (such as TNF - α, IL-6, IL-1 β). Its anti-inflammatory effect has also been confirmed in acute inflammation models such as carrageenan induced paw swelling in mice.
3. Other activities:
Preliminary studies also suggest that Naoyanghuasu III may have analgesic and insecticidal activities, but research in these areas is relatively scarce and requires further exploration.
Mechanism of action and molecular targets
The anti-tumor effect of Naoyanghuasu III involves multiple targets and pathways, reflecting the complexity of the mechanism of action of natural products. Existing research has revealed its interactions with multiple key tumor associated target proteins:
1. Inducing cell apoptosis: This is one of the core anti-cancer mechanisms of Naoyanghuasu III. It mainly induces apoptosis of the mitochondrial pathway by regulating members of the Bcl-2 protein family. Research has shown that anthocyanins III can Downregulation of anti apoptotic proteins Bcl-2 and Mcl-1 At the same time, it may upregulate the expression of pro apoptotic proteins such as Bax, leading to a decrease in mitochondrial membrane potential, release of cytochrome C, and activation of the caspase cascade reaction, ultimately resulting in cell apoptosis.
2. Inhibit cell proliferation, invasion, and metastasis:
- Inhibition of STAT3 signaling pathway: STAT3 is an important oncogenic transcription factor. Naoyanghuasu III can inhibit the phosphorylation (activation) of STAT3, block its nuclear translocation, thereby downregulating the expression of downstream target genes (such as Cyclin D1, Bcl-2, MMP-2/9), inhibiting cell cycle progression and survival.
- Inhibition of matrix metalloproteinases (MMPs): Naoyanghuasu III can significantly improve Downregulate MMP-2 and MMP-9 Expression and activity. MMPs are key enzymes that degrade extracellular matrix, promote tumor invasion and metastasis, and their inhibition helps to block the process of tumor metastasis.
- Inhibition of Topoisomerase (TOP): Research suggests that crocin III may interfere Topoisomerase I (TOP1) and Topoisomerase II α (TOP2A) The activity affects DNA replication and repair, leading to DNA damage and inhibiting tumor cell proliferation.
3. Regulating hormone related pathways:
- Affects estrogen receptor (ESR1) and aromatase (CYP19A1): For hormone dependent tumors (such as breast cancer), rhododendron III shows interference on estrogen signaling pathway. It may act as a regulator of estrogen receptors and inhibit Aromatase (CYP19A1) The latter is a key enzyme in estrogen synthesis, thereby cutting off estrogen driven tumor growth signals.
4. Interference with hypoxia and survival signals:
- Inhibition of HIF-1 α: In the hypoxic microenvironment of tumors, hypoxia inducible factor-1 alpha (HIF-1 alpha) is activated, promoting tumor adaptation and progression. Naoyanghuasu III Downregulate HIF-1 αThe protein level may inhibit adaptive processes such as angiogenesis (VEGF expression) and glycolysis.
- Regulating the MAPK pathway: As an important intracellular signaling pathway, the MAPK/ERK pathway (involving MAPK1/ERK2）Participate in cell proliferation, differentiation, and survival. The inhibition of this pathway by Naoyanghuasu III may also be one of the mechanisms underlying its anti proliferative effect.
In summary, Naoyanghuasu III forms a multi-target synergistic network by simultaneously acting on apoptosis regulatory proteins (MCL1, BCL2), signal transduction molecules (STAT3, MAPK1), extracellular matrix degrading enzymes (MMP2), DNA processing enzymes (TOP1, TOP2A), hypoxia adaptation factor (HIF1A), and hormone related targets (ESR1, CYP19A1), jointly inhibiting tumor growth, survival, invasion, and metastasis.
Evaluation of drug properties and pharmacokinetics
Although Naoyanghuasu III exhibits strong activity in vitro, its drug like and pharmacokinetic properties are key factors determining its successful development as a drug.
1. Preliminary evaluation of drug properties:
Based on the physical and chemical parameters mentioned earlier, Naoyanghuasu III basically conforms to Lipinski's "Five Rules" (Ro5), indicating its potential for oral absorption. However, its TPSA value is relatively high (>100 Å ²), which may affect its cell membrane permeability and oral bioavailability. Low blood-brain barrier permeability prediction limits its use in treating central nervous system tumors, but may reduce the risk of central neurotoxicity. The absence of hERG inhibition and Ames mutagenicity warning is its advantage, but it must be confirmed through rigorous experiments.
2. Current status of pharmacokinetic research:
At present, there are relatively limited reports on the pharmacokinetic studies of the Naoyanghuasu III system, which is a shortcoming in its development process. Some preliminary animal (rat) pharmacokinetic studies have shown that:
- Absorption and bioavailability: After oral administration, kaempferol III can be absorbed in the gastrointestinal tract, but its absolute bioavailability may not be high, which is related to its solubility and first pass effect.
- Distribution: After entering the systemic circulation, drugs can be distributed to multiple tissues, but their accumulation in tumor tissues is still unclear. Its low BBB permeability needs to be verified in experiments.
- Metabolism: As a diterpenoid compound, kaempferol III is likely to be metabolized in the liver through phase I (such as CYP450 enzyme system) and phase II (such as glucuronidation and sulfation) reactions. It is crucial to clarify the main metabolic enzymes and metabolites for evaluating drug interactions and toxicity.
- Excretion: Preliminary data suggests that it may be mainly excreted through bile and kidneys.
3. Safety (toxicity) considerations:
The safety of Ranunculin III is a key concern due to its toxicity. In vitro cytotoxicity experiments have shown that its toxicity to normal cells is usually lower than that to tumor cells, indicating a certain degree of selectivity. However, acute and long-term toxicity experiments in vivo are essential, and a systematic evaluation of their potential damage to important organs such as the liver, kidneys, and heart is needed. The therapeutic window (the range between effective dose and toxic dose) needs to be precisely defined.
Clinical application prospects and prospects
As a multi-target anti-tumor natural lead compound, Naoyanghuasu III has broad clinical application prospects, but also faces many challenges.
1. Development direction:
- New anti-tumor drug candidates: Given its activity against various solid tumors and hematological malignancies, as well as its unique multi-target mechanism of action, kaempferol III has the potential to be developed into a novel small molecule anticancer drug with broad-spectrum or targeting specific targets (such as STAT3, Bcl-2 family). Especially for tumors that are resistant to existing chemotherapy drugs, it may provide new treatment options.
- Combination therapy strategy: The combination of Naoyanghuasu III with conventional chemotherapy drugs (such as paclitaxel, cisplatin) or targeted drugs may produce synergistic effects, reduce their respective dosages, minimize toxic side effects, and overcome drug resistance.
- Structural optimization and derivative development: Using it as the parent nucleus for structural modification is a key pathway to enhance its activity and improve its drug properties. For example, by modifying its hydroxyl, carbonyl, or lactone ring, it is possible to improve its solubility, membrane permeability, metabolic stability, or target selectivity, thereby obtaining candidate drugs with better properties.
2. Challenges faced:
- Lack of systematic pharmacokinetic and toxicological data: At present, most research is focused on in vitro activity and preliminary mechanisms, and comprehensive in vivo PK/PD (pharmacodynamics) studies, safety pharmacology, and GLP toxicology studies urgently need to be carried out.
- The mechanism of action network needs further clarification: Although multiple targets have been identified, the primary and secondary relationships between these targets, upstream and downstream regulatory networks, and their specificity in different tumor types still need to be further elucidated.
- Natural source limitations and synthesis: Extracting yields from plants is limited and influenced by seasons and resources. Therefore, the development of fully or semi synthetic routes for the synthesis of anthocyanins III is crucial for ensuring raw material supply and structural modification.
- Formulation development: To address the potential issues of solubility and stability, it is necessary to develop suitable drug delivery systems, such as nanoparticles, liposomes, cyclodextrin inclusion complexes, etc., to improve their delivery efficiency and targeting.
Conclusion
Naoyanghuasu III is a diterpenoid compound with significant research value discovered from the traditional toxic plant Rhododendron simsii. It has become a highlight in the field of natural product anti-tumor research due to its significant anti-tumor and anti-inflammatory activities, as well as its unique mechanism of acting on multiple key tumor targets such as MCL1, BCL2, STAT3, MMP2, TOP1/2A, etc. Although it has shown certain potential in drug development, systematic and in-depth pharmacokinetic and toxicological studies, as well as chemical modifications based on structural optimization, are the necessary steps to push it from a lead compound to a preclinical candidate drug. In the future, through interdisciplinary collaboration and integration of modern drug discovery technologies, Naoyanghuasu III is expected to be developed into a novel and effective anti-tumor drug with a novel mechanism of action, or provide a new weapon for combination therapy, ultimately benefiting cancer patients worldwide.
